Nexolina 5mg Tablets contain the active ingredient Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Nexolina does not stimulate insulin secretion or increase glucose uptake, but rather works by inhibiting the degradation of incretin hormones, thereby enhancing insulin synthesis and reducing glucagon secretion. The recommended dose is one 5mg tablet orally once daily, with or without food. Nexolina is contraindicated in patients with a history of hypersensitivity to linagliptin or any of its excipients. Common adverse reactions include upper respiratory tract infections, headache, and nasopharyngitis. For optimal glycemic control, Nexolina should be used in combination with other antidiabetic agents as necessary. Regular monitoring of HbA1c, fasting plasma glucose, and renal function is recommended during treatment.